Temes Christina M, Zanarini Mary C
McLean Hospital, Belmont, MA, USA.
Harvard Medical School, Boston, MA, USA.
F1000Res. 2019 Apr 26;8. doi: 10.12688/f1000research.18561.1. eCollection 2019.
Borderline personality disorder (BPD) is a serious psychiatric disorder that affects multiple symptomatic domains and is associated with an increased risk of suicidality. Several empirically supported treatments for BPD have been developed in recent years for adults with BPD. More recent work has focused on tailoring or applying (or both) these existing treatments to specific patient populations, including patients with certain types of comorbidity (for example, BPD and post-traumatic stress disorder or antisocial personality disorder) and younger patients. Other work has involved developing treatments and models of treatment delivery that address concerns related to access of care. Relatedly, new adjunctive and technology-assisted interventions have been developed, adding to the growing repertoire of treatment options for these patients. Advances in the last several years address specific treatment needs and offer cost-efficient options for this diverse patient population.
边缘性人格障碍（BPD）是一种严重的精神疾病，会影响多个症状领域，并与自杀风险增加有关。近年来，针对成年BPD患者开发了几种经实证支持的治疗方法。最近的工作重点是针对特定患者群体调整或应用（或两者兼而有之）这些现有治疗方法，包括患有某些类型合并症（例如，BPD与创伤后应激障碍或反社会人格障碍）的患者以及年轻患者。其他工作涉及开发解决与医疗服务可及性相关问题的治疗方法和治疗提供模式。相关地，已经开发了新的辅助和技术辅助干预措施，为这些患者增加了越来越多的治疗选择。过去几年的进展满足了特定的治疗需求，并为这个多样化的患者群体提供了具有成本效益的选择。
